According to Australian media reports on June 13th, four e-cigarette dealers in Sydney have been fined a total of AUD 588,840 for allegedly illegally importing 379,600 unregistered e-cigarette products from IGET, GUNPOD, and HQD.
It has been reported that the Australian Therapeutic Goods Administration (TGA) has tested these products and found that they contain ingredients prohibited under the Nicotine e-Cigarette Products Standard (TGO 110) 2021 order.
It is reported that TGA will seize and destroy these products based on the recommendations of the pharmaceutical regulatory agency.
Professor Nick Zwar, Chair of the Smoking Cessation Guidelines Expert Advisory Group at the Royal Australian College of General Practitioners (RACGP), stated that the profits from e-cigarette products are high, making the fines too insignificant.
Professor Zwar cited an example of high fines that exist in international jurisdictions, such as South Korea, where fines for each violation can reach $200,000 USD (approximately $294,000 AUD), far surpassing those in Australia.
As such, I have some doubts about the adequacy of the current fine and I have raised this concern with the government.
Professor Zwar stated that although the fine is small, the fact that regulatory authorities are beginning to enforce the law is a positive sign, indicating that the TGA is taking a stricter stance on e-cigarettes.
He said, "I believe we will see more of these situations in the future. Despite laws prohibiting the import of nicotine products, many products have still made their way into the country without proper labeling of their nicotine content. Tests conducted by universities and other organizations have revealed that over 80% of these products contain nicotine.
So currently, the only proven method is to send products to a laboratory for analysis, making enforcement very difficult. However, by directly prohibiting the import of non-medical e-cigarette products, they can now be seized at customs, making enforcement easier," he added.
On June 15th, 2FIRSTS issued an interview invitation to the Therapeutic Goods Administration (TGA) of Australia and will continue to bring follow-up reports. Stay tuned for further updates.
Reference(s):
The TGA's recent actions against vaping indicate that more regulation may be on the horizon.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
